|Day's Range||53.9000 - 54.8200|
|52 Week Range||46.0100 - 77.1200|
|PE Ratio (TTM)||18.75|
|Dividend & Yield||1.56 (2.89%)|
|1y Target Est||N/A|
It's Celgene versus Bristol-Myers Squibb in a head-to-head matchup. Which drug stock wins as the better pick for long-term investors?
Merck & CO, Inc. (MRK) announced that it has bought exclusive worldwide license from Teijin Pharma for the development, manufacture and commercialization of an investigational preclinical anti-tau antibody.
Merck (MRK) got another approval for Keytruda while Aerie shot up on positive data.